We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 06, 2020

Adjuvant Therapy With Imatinib in Patients With High-Risk Molecularly Profiled GIST

European Journal of Surgical Oncology


Additional Info

European Journal of Surgical Oncology
The Analysis of 3-Year Adjuvant Therapy With Imatinib in Patients With High-Risk Molecular Profiled Gastrointestinal Stromal Tumors (GIST) Treated in Routine Practice
Eur J Surg Oncol 2020 Aug 16;[EPub Ahead of Print], P Rutkowski, M Ziętek, B Cybulska-Stopa, J Streb, S Głuszek, M Jankowski, K Łopacka-Szatan, M Las-Jankowska, P Hudziec, A Klimczak, T Olesiński, T Świtaj, H Koseła-Paterczyk, E Bylina, C Osuch

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading